直接转入重新编码蛋白诱导多能干细胞产生

已有研究表明,通过转入体细胞Oct4、Sox2、Klf4、c-Myc四个转录因子,将使得体细胞诱导成为多能干细胞。但是,病毒转染的手段可能会造成如随机重组至基因突变等很多的危险因素。哈佛大学的研究人员通过转入体细胞Oct4、Sox2、Klf4和c-     

体细胞重编程为诱导多能干细胞

诱导多功能性干细胞（induced pluripotent stem cells,iPS细胞）是通过导入特定的转录因子（如Oct3/4、Sox2、c-Myc和Klf4等）将体细胞诱导重编程为多能性干细胞,其功能与胚胎干细胞相似.iPS细胞的建立,在生命科学领域引起了新的轰动.目前,iPS细胞的研究领域在转录因子的优化、iPS细胞的筛选、载体的运用、体细胞种类的选择和iPS细胞的应用等方面取得突破进展,但仍然存在致癌性、效率低等一系列急需解决的问题.     

微核糖核酸簇miR-290-295促进体细胞重编程

目的：探究干细胞中表达丰度最高的微核糖核酸簇miR-290-295对体细胞重编程的影响。方法：使用逆转录病毒载体将miR-290-295簇在小鼠体细胞中过表达,研究其促进体细胞重编程为诱导性多能干细胞(induced pluripotent stem cells, iPSCs)以及此过程对细胞功能的影响。结果：miR-290-295簇的过表达在三因子(Sox2、Klf4、Oct4)诱导体系中能够显著提高小鼠体细胞重编程的效率;过表达miR-290-295簇能够促进重编程中多能性标记基因的上调与体细胞标记基因的下调,同时也会促进间质-上皮细胞转化(mesenchymal-epithelial transition, MET)标记基因的表达。结论：miR-290-295簇对小鼠体细胞重编程具有促进作用,这有助于深入理解干细胞多能性和重编程的RNA调节机制,为开发新型诱导体系提供了新视角。     

诱导多能干细胞研究进展

成熟的体细胞过表达转录激活因子Oct4、Sox2、Klf4和c-Myc能够转化为具有多能性的干细胞,称为诱导多能干细胞。类似于胚胎干细胞,诱导多能性干细胞具有自我更新和多向分化潜能性两个主要特征。同胚胎干细胞相比,诱导多能干细胞不仅能够为以细胞替代治疗为核心的再生医学提供无限的细胞来源,而且有望解决胚胎干细胞临床开发面临的伦理道德及免疫排斥问题。从诱导多能干细胞技术的建立、重编程的机理及其在临床中的应用几方面作简要综述。     

体细胞直接转化为多能干细胞的新方法

胚胎干细胞具有自我复制、高度增殖、多向分化潜能、可植入性和重建能力等特征.对于诸如青少年糖尿病、帕金森综合症和心脏病等需要通过细胞移植来治疗的疾病而言,从人的囊胚内细胞团获得胚胎干细胞系是最理想的供体来源.然而,目前实验和医疗还要考虑到利用人类胚胎的一些伦理问题和组织排异反应.避免这些问题的可能途径就是通过已分化体细胞的重新编程来直接转化为诱导性多能干细胞,它们具有类似ES细胞的功能.目前,获得诱导性多能干细胞的设想已初步实现了从老鼠到人的突破.以下主要对体细胞直接转化为诱导性多能干细胞的研究现状、方法和转录因子在诱导体细胞重新编程中发挥的作用等内容进行了概述,以期为干细胞研究者进行更深入的研究提供一定的借鉴.     

维持胚胎干细胞多能性和自我更新的转录因子Oct-4/ Nanog以及相关的调控网络

Oct-4和Nanog是两种维持干细胞多能性和自我更新的转录因子, 它们通过结合靶基因调控区, 选择性地抑制分化基因表达或促进多能性基因表达。它们通常只在多能干细胞中表达, 在分化细胞中不表达。在不同的发育阶段, 它们的表达量受到特异调控, 并且分别与Sox-2、FoxD3等其他转录因子以及LIF、BMP等胞外信号通路互相作用, 形成一个复杂的转录调节crosstalk网络, 在特异时空激活或抑制靶基因的转录; 通过互相制约最终决定干细胞是保持多能性还是分化, 以及向哪个方向分化。此外, Oct-4和Nanog对体细胞重编程为多能细胞也有重要作用。     

改变细胞命运的重编程

体细胞重编程是指用特定方法使已分化的细胞重新获得多能性的过程,可通过核移植、细胞融合、多能细胞提取物共培养和诱导性多能干细胞等途径实现。其中,诱导性多能干细胞技术发展最为迅速,应用前景广阔。现主要介绍重编程领域近年的研究进展。     

诱导性多能干细胞研究技术的现状与前景

2006年Takahashi研究小组成功地将小鼠的胚胎成纤维细胞和鼠尾成纤维细胞重编成为诱导性多能干细胞(iPSC),开创了体细胞重编程的全新方法,所得iPSC具有和胚胎干细胞相似的生物学特性,不仅解决了人类胚胎干细胞研究所面临的伦理学困境和免疫排斥问题,而且进一步深化了对细胞多能性和基因组重编程的认识,再次掀起了干细胞研究的热潮。iPSC结合基因治疗和细胞治疗的成果已经应用到动物疾病模型上。iPSC能够自我更新并维持未分化状态,可分化为3个胚层来源的所有细胞,参与形成机体所有组织和器官,体外定向诱导能够分化出各种成体细胞,在理论研究和临床应用等方面都极具应用价值。但iPSC技术也存在一系列问题需要研究解决。     

诱导重编程的表观遗传调控研究进展

表观遗传调控是细胞命运变化与决定的重要基础之一。2006年,日本科学家山中伸弥发现通过4个转录因子Oct4、Sox2、Klf4和c-Myc可以将已经分化的体细胞逆转回与胚胎干细胞相似的多能性状态,获得诱导多能干细胞(induced pluripotent stem cells,i PSCs)。这种诱导重编程技术不仅是干细胞技术的一大突破,也提供了关键的体外模型用于研究细胞重编程的表观遗传机制。对该机制的深入理解将推动人类自由操纵细胞命运的进程,从而有望治疗各种因功能细胞、组织、器官缺失退化引发的疾病。从诱导重编程的表观遗传调控方向的研究进展出发,阐述通过诱导重编程发现的关键细胞命运转变表观调控机制,展望未来的主要研究目标。     

重编程与成纤维细胞直接转化为其它终末分化细胞

从干细胞(包括胚胎干细胞、成体干细胞)到体细胞克隆再到诱导性多能干细胞(iPSCs)的研究,这是生命科学领域近三十年研究发展的主线。当前,iPSCs的研究成为最大的热点。随着人类社会进入二十一世纪第二个十年,干细胞研究会怎样发展?这是我们需要慎重考虑的问题。细胞生物学是上世纪70年代通过分子生物学发展和推动、并深入到细胞范围内由经典细胞学研究演化而来的。到了本世纪初已代替分子生物学成     

Low-molecular-weight inhibitors of cell differentiation enable efficient growth of mouse iPS cells under feeder-free conditions

Embryonic stem cells and induced pluripotent stem (iPS) cells are usually maintained on feeder cells derived from mouse embryonic fibroblasts (MEFs). In recent years, the cell culture of iPS cells under serum- and feeder-free conditions is gaining attention in overcoming the biosafety issues for clinical applications. In this study, we report on the use of multiple small-molecular inhibitors (i.e., CHIR99021, PD0325901, and Thiazovivin) to efficiently cultivate mouse iPS cells without feeder cells in a chemically-defined and serum-free condition. In this condition, we showed that mouse iPS cells are expressing the Nanog, Oct3/4, and SSEA-1 pluripotent markers, indicating that the culture condition is optimized to maintain the pluripotent status of iPS cells. Without these small-molecular inhibitors, mouse iPS cells required the adaptation period to start the stable cell proliferation. The application of these inhibitors enabled us the shortcut culture method for the cellular adaptation. This study will be useful to efficiently establish mouse iPS cell lines without MEF-derived feeder cells.     

Activation of the Imprinted Dlk1-Dio3 Region Correlates with Pluripotency Levels of Mouse Stem Cells

Low reprogramming efficiency and reduced pluripotency have been the two major obstacles in induced pluripotent stem (iPS) cell research. An effective and quick method to assess the pluripotency levels of iPS cells at early stages would significantly increase the success rate of iPS cell generation and promote its applications. We have identified a conserved imprinted region of the mouse genome, the Dlk1-Dio3 region, which was activated in fully pluripotent mouse stem cells but repressed in partially pluripotent cells. The degree of activation of this region was positively correlated with the pluripotency levels of stem cells. A mammalian conserved cluster of microRNAs encoded by this region exhibited significant expression differences between full and partial pluripotent stem cells. Several microRNAs from this cluster potentially target components of the polycomb repressive complex 2 (PRC2) and may form a feedback regulatory loop resulting in the expression of all genes and non-coding RNAs encoded by this region in full pluripotent stem cells. No other genomic regions were found to exhibit such clear expression changes between cell lines with different pluripotency levels; therefore, the Dlk1-Dio3 region may serve as a marker to identify fully pluripotent iPS or embryonic stem cells from partial pluripotent cells. These findings also provide a step forward toward understanding the operating mechanisms during reprogramming to produce iPS cells and can potentially promote the application of iPS cells in regenerative medicine and cancer therapy.     

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem (ES) cells. Little is known about factors that induce this reprogramming. Here, we demonstrate induction of pluripotent stem cells from mouse embryonic or adult fibroblasts by introducing four factors, Oct3/4, Sox2, c-Myc, and Klf4, under ES cell culture conditions. Unexpectedly, Nanog was dispensable. These cells, which we designated iPS (induced pluripotent stem) cells, exhibit the morphology and growth properties of ES cells and express ES cell marker genes. Subcutaneous transplantation of iPS cells into nude mice resulted in tumors containing a variety of tissues from all three germ layers. Following injection into blastocysts, iPS cells contributed to mouse embryonic development. These data demonstrate that pluripotent stem cells can be directly generated from fibroblast cultures by the addition of only a few defined factors.     

Generation of Induced Pluripotent Stem Cell Lines from Tibetan Miniature Pig

Induced pluripotent stem cell (iPS) technology appears to be a general strategy to generate pluripotent stem cells from any given mammalian species. So far, iPS cells have been reported for mouse, human, rat, and monkey. These four species have also established embryonic stem cell (ESC) lines that serve as the gold standard for pluripotency comparisons. Attempts have been made to generate porcine ESC by various means without success. Here we report the successful generation of pluripotent stem cells from fibroblasts isolated from the Tibetan miniature pig using a modified iPS protocol. The resulting iPS cell lines more closely resemble human ESC than cells from other species, have normal karyotype, stain positive for alkaline phosphatase, express high levels of ESC-like markers (Nanog, Rex1, Lin28, and SSEA4), and can differentiate into teratomas composed of the three germ layers. Because porcine physiology closely resembles human, the iPS cells reported here provide an attractive model to study certain human diseases or assess therapeutic applications of iPS in a large animal model.     

疾病特异诱导多能干细胞研究进展

通过病毒或非病毒转导体系,在小鼠和人的体细胞中人为表达几个与细胞多能性相关的转录因子,从而使细胞达到类似于胚胎干细胞（embryonic stem cells,ESCs）状态,是近年来新发展起来的体细胞重编程技术。这些被重编程的细胞称为诱导多能干细胞（induced pluripotent stem cells,iPS细胞）。这项技术为获得患者和疾病特异的多能干细胞提供了新的途径。患者和疾病特异的iPS细胞的获得,不仅在避免免疫排斥的宿主特异的细胞移植治疗上有广泛前景,并对了解疾病发生机理、药物筛选和毒性研究有着重要的意义。该文综述从iPS细胞技术的发明入手,着重讨论疾病iPS细胞的研究进展及其在应用于治疗时亟需解决的问题。     

iPS细胞的遗传安全性

自2006年Takahashi和Yamanaka首次成功地从小鼠成纤维细胞诱导得到诱导多能性干细胞(Induced pluripotent stem cells, iPS细胞)以来, iPS细胞由于其潜在的广阔应用前景而迅速成为干细胞研究领域的新热点; 与此同时, iPS细胞的遗传安全性也越来越多地受到人们的关注。文章将对iPS细胞遗传安全性的研究进展进行综述, 分析造成iPS细胞遗传不稳定的可能原因, 希望可以促进对iPS细胞诱导条件的优化, 获得遗传上较为安全的iPS细胞。     

iPS细胞的遗传安全性

自2006年Takahashi和Yamanaka首次成功地从小鼠成纤维细胞诱导得到诱导多能性干细胞(Induced pluripotent stem cells,iPS细胞)以来,iPS细胞由于其潜在的广阔应用前景而迅速成为干细胞研究领域的新热点;与此同时,iPS细胞的遗传安全性也越来越多地受到人们的关注。文章将对iPS细胞遗传安全性的研究进展进行综述,分析造成iPS细胞遗传不稳定的可能原因,希望可以促进对iPS细胞诱导条件的优化,获得遗传上较为安全的iPS细胞。